Ghrelin receptor agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Ghrelin Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ghrelin Receptor Agonist: Overview
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G?protein?coupled receptor called the growth hormone secretagogue receptor 1a (GHS?R1a). Another GHS?R cDNA is produced by alternative splicing which produces a COOH?terminal truncated form (GHS?R1b) that is pharmacologically inactive. The GHS?R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS?R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
Further product details are provided in the report……..
Ghrelin Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Ghrelin Receptor Agonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Ghrelin Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ghrelin Receptor Agonist: Overview
Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G?protein?coupled receptor called the growth hormone secretagogue receptor 1a (GHS?R1a). Another GHS?R cDNA is produced by alternative splicing which produces a COOH?terminal truncated form (GHS?R1b) that is pharmacologically inactive. The GHS?R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS?R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.
This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ghrelin Receptor Agonist Emerging Drugs
- Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Further product details are provided in the report……..
Ghrelin Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Ghrelin Receptor Agonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Ghrelin Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.
Ghrelin Receptor Agonist Report Insights
- Ghrelin Receptor Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Ghrelin Receptor Agonist drugs?
- How many Ghrelin Receptor Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ghrelin Receptor Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Helsinn Therapeutics/Ono Pharmaceutical
- AEterna Zentaris
- Anamorelin HCl
- Macimorelin
Introduction
Executive Summary
Ghrelin Receptor Agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ghrelin Receptor Agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ghrelin Receptor Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ghrelin Receptor Agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Macimorelin: AEterna Zentaris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ghrelin Receptor Agonist Key Companies
Ghrelin Receptor Agonist Key Products
Ghrelin Receptor Agonist- Unmet Needs
Ghrelin Receptor Agonist- Market Drivers and Barriers
Ghrelin Receptor Agonist- Future Perspectives and Conclusion
Ghrelin Receptor Agonist Analyst Views
Ghrelin Receptor Agonist Key Companies
Appendix
Executive Summary
Ghrelin Receptor Agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ghrelin Receptor Agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ghrelin Receptor Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ghrelin Receptor Agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Macimorelin: AEterna Zentaris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ghrelin Receptor Agonist Key Companies
Ghrelin Receptor Agonist Key Products
Ghrelin Receptor Agonist- Unmet Needs
Ghrelin Receptor Agonist- Market Drivers and Barriers
Ghrelin Receptor Agonist- Future Perspectives and Conclusion
Ghrelin Receptor Agonist Analyst Views
Ghrelin Receptor Agonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ghrelin Receptor Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ghrelin Receptor Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ghrelin Receptor Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ghrelin Receptor Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
